Publications by authors named "Piera Federico"

Claim this Profile
S
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab.
Andrea Dalbeni, Filippo Cattazzo, Marco Vicardi, Eugenio Franceschini, Claudia Campani, Piera Federico

Sci Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study.
Alessandro Vitale, Jung Sun Kim, Giuseppe Cabibbo, Andrea Casadei-Gardini, Massimo Iavarone, Federico Rossari, Piera Federico

Liver Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib Is Highly Effective in Patients with Hepatocellular Carcinoma Related to Both Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Etiology: A Propensity Score Analysis.
Rodolfo Sacco, Edoardo G Giannini, Raffaella Tortora, Giovan Giuseppe Di Costanzo, Andrea Mega, Piera Federico

Cancers (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab.
Bernardo Stefanini, Fabio Piscaglia, Fabio Marra, Massimo Iavarone, Caterina Vivaldi, Piera Federico

Liver Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancements in immunotherapy for hepatocellular carcinoma.
Sara Ascari, Rusi Chen, Caterina Vivaldi, Bernardo Stefanini, Andrea De Sinno, Piera Federico

Expert Rev Anticancer Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma.
Francesco Tovoli, Dante Pio Pallotta, Caterina Vivaldi, Claudia Campani, Piera Federico

Dig Liver Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatments, prognostic factors, and genetic heterogeneity in advanced cholangiocarcinoma: A multicenter real-world study.
Alessandro Ottaiano, Mariachiara Santorsola, Anna Diana, Andrea Belli, Maria Luisa Lentini Graziano, Piera Federico

Cancer Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transversal Perspectives of Integrative Oncology Care in Gastric and Lobular Breast Cancer.
Emilio Francesco Giunta, Gianluca Arrichiello, Annalisa Pappalardo, Piera Federico, Angelica Petrillo

Cancer Treat Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-hereditary early onset gastric cancer: An unmet medical need.
Angelica Petrillo, Piera Federico, Gianpaolo Marte, Carlo Liguori, Andreas Seeber

Curr Opin Pharmacol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis.
Rodolfo Sacco, Daryl Ramai, Raffaella Tortora, Giovan Giuseppe di Costanzo, Michela Emma Burlone, Piera Federico

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact.
Piera Federico, Emilio Francesco Giunta, Andrea Tufo, Francesco Tovoli, Angelica Petrillo

Cancers (Basel)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second-line clinical trials.
Francesco Tovoli, Ingrid Garajová, Fabio Gelsomino, Massimo Iavarone, Piera Federico

Liver Int· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetic Regulation in Melanoma: Facts and Hopes.
Emilio Francesco Giunta, Gianluca Arrichiello, Marcello Curvietto, Annalisa Pappalardo, Davide Bosso, Piera Federico

Cells· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting.
Annalisa Pappalardo, Emilio Francesco Giunta, Giuseppe Tirino, Luca Pompella, Piera Federico

Front Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma.
Francesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, Lorenza Rimassa, Gianluca Masi, Piera Federico

Liver Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them.
Angelica Petrillo, Emilio Francesco Giunta, Annalisa Pappalardo, Davide Bosso, Laura Attademo, Piera Federico

J Clin Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to Treat Hepatocellular Carcinoma in Elderly Patients.
Piera Federico, Emilio Francesco Giunta, Annalisa Pappalardo, Andrea Tufo, Gianpaolo Marte

Pharmaceuticals (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Surgery for the Treatment of Gastric Cancer Liver Metastases: A Systematic Review of the Literature and Meta-Analysis of Prognostic Factors.
Gianpaolo Marte, Andrea Tufo, Francesca Steccanella, Ester Marra, Piera Federico

J Clin Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
Margaret Ottaviano, Marcello Curvietto, Pasquale Rescigno, Marianna Tortora, Giovannella Palmieri, Piera Federico

J Immunother Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives.
Piera Federico, Angelica Petrillo, Pasqualina Giordano, Davide Bosso, Antonietta Fabbrocini

Cancers (Basel)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate.
Giuseppe Di Lorenzo, Guru Sonpavde, Gregory Pond, Giuseppe Lucarelli, Sabrina Rossetti, Piera Federico

Eur Urol Focus· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival in a patient with metastatic squamous cell lung carcinoma: A case report.
Emiddio Barletta, Piera Federico, Vincenza Tinessa, Domenico Germano, Lucia Cannella

Mol Clin Oncol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review.
Giuseppe Di Lorenzo, Piera Federico, Sabino De Placido, Carlo Buonerba

Crit Rev Oncol Hematol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving landscape in advanced penile cancer.
Carlo Buonerba, Giuseppe Di Lorenzo, Giuseppe Calderoni, Matteo Ferro, Francesco Perri, Piera Federico

Future Sci OA· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.
Orazio Caffo, Cinzia Ortega, Giuseppe Di Lorenzo, Teodoro Sava, Ugo De Giorgi, Piera Federico

Urol Oncol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis